PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Epilepsy: An overview PART 05: Pipeline analysis PART 06: Key buying criteria for anti-epileptic drugs PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by generation of drugs • First-generation anti-epileptic drugs • Second-generation anti-epileptic drugs • Third-generation anti-epileptic drugs PART 09: Market segmentation by spectrum of activity • Narrow-spectrum anti-epileptic drugs • Broad-spectrum anti-epileptic drugs PART 10: Market segmentation by type of seizures • Partial onset seizures • Generalized seizures PART 11: Geographical segmentation • Global epilepsy drugs market by geography 2016-2020 • Epilepsy drugs market in Americas • Epilepsy drugs market in US • Epilepsy drugs market in EMEA • Epilepsy drugs market in APAC • Epilepsy drugs market in Japan • Epilepsy drugs market in Australia • Epilepsy drugs market in China • Epilepsy drugs market in India PART 12: Market drivers • Tentative approval of late-stage pipeline molecules • Special regulatory designations • Development of novel therapeutics using innovative technologies PART 13: Impact of drivers PART 14: Market challenges • Social stigma associated with epilepsy • Growing use of seizure management devices is a threat to drug therapies • Gradual decrease in incentives/investment by vendors for new drug development PART 15: Impact of drivers and challenges PART 16: Market trends • Development of devices and smartphone apps to detect seizures and track medications • Reformulation of marketed drugs • Increased uptake of new-generation drugs PART 17: Vendor landscape • Competitive scenario • Key news PART 18: Key vendor analysis • Eisai • GSK • Pfizer • UCB • Other prominent vendors PART 19: Appendix • List of abbreviations PART 20: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Pipeline portfolio: Epilepsy drugs Exhibit 03: Percentage share of pipeline molecules for global epilepsy drugs market Exhibit 04: Key buying criteria for anti-epileptic drugs Exhibit 05: Global epilepsy drugs market snapshot: Developed and emerging markets 2015 Exhibit 06: Global epilepsy drugs market 2015-2020 ($ billions) Exhibit 07: A few research studies targeting cause of epilepsy Exhibit 08: Segmentation of marketed anti-epileptic drugs based on mechanism of action Exhibit 09: Five forces analysis Exhibit 10: Timeline of development of anti-epileptic drugs Exhibit 11: Segmentation of global anti-epileptic drugs market based on generation of drugs 2015 Exhibit 12: Opportunity analysis of global epilepsy drugs market by generation of drugs Exhibit 13: Segmentation of global epilepsy drugs market by the spectrum of activity of drugs 2015 Exhibit 14: Segmentation of global epilepsy drugs market based on type of seizures Exhibit 15: Global epilepsy drugs market by geography 2015-2020 Exhibit 16: Global epilepsy drugs market by geography 2015 and 2020 Exhibit 17: Global epilepsy drugs market by geography 2015-2020 ($ billions) Exhibit 18: Epilepsy drugs market in Americas 2015-2020 ($ billions) Exhibit 19: Epilepsy drugs market in Americas by geography 2015 Exhibit 20: Comparison of US healthcare system: Before and after reforms Exhibit 21: Epilepsy drugs market in US 2015-2020 ($ billions) Exhibit 22: Epilepsy drugs market in EMEA by geography 2015 Exhibit 23: Epilepsy drugs market in EMEA 2015-2020 ($ billions) Exhibit 24: Epilepsy drugs market in APAC 2015-2020 ($ billions) Exhibit 25: Epilepsy drugs market in APAC by geography 2015 Exhibit 26: Epilepsy drugs market in Japan 2015-2020 ($ millions) Exhibit 27: Epilepsy drugs market in Australia 2015-2020 ($ millions) Exhibit 28: Epilepsy drugs market in China 2015-2020 ($ millions) Exhibit 29: Epilepsy drugs market in India 2015-2020 ($ millions) Exhibit 30: Impact of drivers Exhibit 31: Impact of drivers and challenges Exhibit 32: Position of key vendors in global epilepsy drugs market 2015 Exhibit 33: Geographical presence of key vendors Exhibit 34: Company portfolio analysis in global epilepsy drugs market 2016-2020 Exhibit 35: Eisai: YoY revenue and growth rate of Fycompa (Americas and EMEA) 2013-2015 ($ millions) Exhibit 36: Eisai: YoY revenue and growth rate of Zonegran (EMEA) 2013-2015 ($ millions) Exhibit 37: Eisai: YoY revenue and growth rate of Banzel (Americas and EMEA) 2013-2015 ($ millions) Exhibit 38: Eisai: YoY revenue and growth rate of Zebinix (EMEA) 2013-2015 ($ millions) Exhibit 39: Eisai: Metrics analysis Exhibit 40: GSK: YoY revenue and growth rate of Lamictal 2013-2015 ($ millions) Exhibit 41: GSK: Metrics analysis Exhibit 42: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions) Exhibit 43: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions) Exhibit 44: Pfizer: Metrics analysis Exhibit 45: UCB: YoY revenue and growth rate of Keppra 2013-2015 ($ millions) Exhibit 46: UCB: Geographical segmentation of Keppra by revenue 2015 Exhibit 47: UCB: YoY revenue and growth rate of Vimpat 2013-2015 ($ millions) Exhibit 48: UCB: Geographical segmentation of Keppra by revenue 2015 Exhibit 49: UCB: Metrics analysis

Eisai, GSK, Pfizer, UCB, Acorda Therapeutics, Alexza Pharmaceuticals, Aprecia Pharmaceuticals, Aurobindo Pharma, Biscayne Pharmaceuticals, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, D-Pharm, F. Hoffmann-La Roche, Grupo Ferrer Internacional, GW Pharmaceuticals, Insero Health, INSYS Therapeutics, Janssen Pharmaceuticals, Ligand Pharmaceuticals, H. Lundbeck, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda, Neurelis, Nobelpharma, Novartis, Orphelia Pharma, SAGE Therapeutics, SciFlour, Sedpr Pharmaceuticals, Shire, SK Biopharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals (US), Supernus Pharmaceuticals, Takeda, Turing Pharmaceuticals, Upsher-Smith, Valeant Pharmaceuticals, Zogenix.